BR112022003474A2 - Vacinas do vírus da hepatite b - Google Patents

Vacinas do vírus da hepatite b

Info

Publication number
BR112022003474A2
BR112022003474A2 BR112022003474A BR112022003474A BR112022003474A2 BR 112022003474 A2 BR112022003474 A2 BR 112022003474A2 BR 112022003474 A BR112022003474 A BR 112022003474A BR 112022003474 A BR112022003474 A BR 112022003474A BR 112022003474 A2 BR112022003474 A2 BR 112022003474A2
Authority
BR
Brazil
Prior art keywords
hbv
vaccines
hepatitis
polypeptides
methods
Prior art date
Application number
BR112022003474A
Other languages
English (en)
Inventor
Bette Korber
Emily Marshall
Eric Bruening
James Theiler
Janet Douglas
Karina Yusim
Original Assignee
Triad Nat Security Llc
Vir Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Triad Nat Security Llc, Vir Biotechnology Inc filed Critical Triad Nat Security Llc
Publication of BR112022003474A2 publication Critical patent/BR112022003474A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

vacinas do vírus da hepatite b. a presente revelação se refere a polinucleotídeos e polipeptídeos isolados e vacinas relacionadas ao vírus da hepatite b (hbv). a presente revelação também se refere a vetores virais para expressar esses polipeptídeos e que podem ser usados em vacinas contra hbv, bem como métodos para proteger um sujeito da infecção por hbv e métodos de tratamento de hbv em um sujeito que compreende administrar os polipeptídeos, vetores ou vacinas descritos no presente documento. métodos para projetar e produzir uma vacina contra hbv que compreendem projetar antígenos de vacina para cobrir a diversidade dentro de uma área geográfica usando uma sequência de aminoácidos de antígeno que cobre eficientemente os epítopos nos genótipos de hbv presentes na área geográfica também são fornecidos no presente documento.
BR112022003474A 2019-08-29 2020-08-28 Vacinas do vírus da hepatite b BR112022003474A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962893546P 2019-08-29 2019-08-29
US201962941125P 2019-11-27 2019-11-27
PCT/US2020/048411 WO2021045969A1 (en) 2019-08-29 2020-08-28 Hepatitis b virus vaccines

Publications (1)

Publication Number Publication Date
BR112022003474A2 true BR112022003474A2 (pt) 2022-05-24

Family

ID=74096044

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022003474A BR112022003474A2 (pt) 2019-08-29 2020-08-28 Vacinas do vírus da hepatite b

Country Status (11)

Country Link
US (1) US20220288195A1 (pt)
EP (1) EP4021923A1 (pt)
JP (1) JP2022545530A (pt)
KR (1) KR20220090497A (pt)
CN (1) CN114729010A (pt)
AU (1) AU2020342385A1 (pt)
BR (1) BR112022003474A2 (pt)
CA (1) CA3149415A1 (pt)
IL (1) IL290924A (pt)
MX (1) MX2022002270A (pt)
WO (1) WO2021045969A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220129A (es) 2019-09-30 2022-05-06 Gilead Sciences Inc Vacunas para vhb y métodos de tratamiento de vhb
WO2023085956A1 (en) * 2021-11-09 2023-05-19 Avalia Immunotherapies Limited Novel therapeutic vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60027581T2 (de) * 1999-10-08 2007-05-10 Celltech Pharma Europe Ltd., Slough Design von immunogene
DK1294893T3 (da) * 2000-06-22 2006-07-03 Ucb Pharma Ltd Modifikation af hepatitis B-kerneantigen
ATE409705T1 (de) * 2001-05-25 2008-10-15 Dobeel Corp Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs
AU2004285983B2 (en) * 2003-10-21 2012-06-28 Alfred Health HBV variants detection and application
EP1766096B1 (en) 2004-05-25 2013-01-02 Oregon Health and Science University Hiv vaccination usingand hcmv-based vaccine vectors
KR20120052352A (ko) * 2009-08-07 2012-05-23 트랜스진 에스.에이. Ｈｂｖ 감염을 치료하는 조성물
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
PL2691530T3 (pl) 2011-06-10 2019-02-28 Oregon Health & Science University Glikoproteiny i rekombinowane wektory CMV
KR101418836B1 (ko) * 2012-04-05 2014-08-13 서울대학교산학협력단 간질환 진단용 마커 및 이의 용도
JP6483033B2 (ja) 2013-03-05 2019-03-13 オレゴン・ヘルス・アンド・サイエンス・ユニバーシティＯｒｅｇｏｎ Ｈｅａｌｔｈ ＆ Ｓｃｉｅｎｃｅ Ｕｎｉｖｅｒｓｉｔｙ Ｔ細胞ターゲティングを調節することができるサイトメガロウイルスベクター
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
CA3002508A1 (en) * 2016-01-12 2017-07-20 Ulrike Protzer Means and methods for treating hbv

Also Published As

Publication number Publication date
MX2022002270A (es) 2022-03-22
AU2020342385A1 (en) 2022-03-31
IL290924A (en) 2022-04-01
WO2021045969A1 (en) 2021-03-11
KR20220090497A (ko) 2022-06-29
EP4021923A1 (en) 2022-07-06
CN114729010A (zh) 2022-07-08
CA3149415A1 (en) 2021-03-11
US20220288195A1 (en) 2022-09-15
JP2022545530A (ja) 2022-10-27

Similar Documents

Publication Publication Date Title
CY1122790T1 (el) Αντι-ανθρωπινου ιου των θηλωματων 16 ε7 τ κυτταρου υποδοχεις
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
CL2021000636A1 (es) Vacuna contra el virus de la peste porcina africana
EA201990085A1 (ru) Рационально разработанный аттенуированный штамм вируса африканской лихорадки свиней для защиты от заражения исходным вирусным изолятом georgia 2007
EA201891415A8 (ru) Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
UY30385A1 (es) Vacuna recombinante contra el virus de la lengua azul
BR112022003474A2 (pt) Vacinas do vírus da hepatite b
PH12020550924A1 (en) Heptatitis b virus (hbv) vaccines and uses thereof
AR061894A1 (es) Vacunas para malaria
CO2019003675A2 (es) Meganucleasas diseñadas especificamente para el reconocimiento de secuencias en el genoma del virus de la hepatitis b.
EA202090759A2 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
WO2017044895A3 (en) MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF
BR112022011099A2 (pt) Tratamento de doenças relacionadas ao vírus da hepatite b
AR108014A1 (es) Vacuna universal para enfermedades virales y método de vacunación
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
EA201790296A1 (ru) Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9
EA201690115A1 (ru) Комбинированные иммуногенные композиции
CO6541529A2 (es) Método, plasmideo y composición para inducir una respuesta inmune contra virus de la dengue basado en vacunas de adn y virus quimericos
PH12017500419A1 (en) Recoded arbovirus and vaccines
BR112017019776A2 (pt) proteínas de fusão que compreendem glicoproteínas de superfície de alfavírus modificadas e antígeno associado a tumor e métodos dos mesmos
MX2019007924A (es) Vacunas contra la influenza.
EA202000369A1 (ru) ЭКСПРЕССИОННЫЙ ВЕКТОР ДЛЯ СОЗДАНИЯ ИММУНОБИОЛОГИЧЕСКОГО СРЕДСТВА ДЛЯ ИНДУКЦИИ СПЕЦИФИЧЕСКОГО ИММУНИТЕТА ПРОТИВ ВИРУСА ТЯЖЕЛОГО ОСТРОГО РЕСПИРАТОРНОГО СИНДРОМА SARS-CoV-2 (ВАРИАНТЫ)
BR112019008584A2 (pt) vacinas de mosaico para vírus de doença de pé-e-boca de sorotipo a
DOP2014000215A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
Tian et al. A promising multiple-epitope recombinant vaccine against classical swine fever virus